A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about CNS Pharmaceuticals Inc’s (CNSP) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Charles Griswold
| Share Statistics | CNSP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.5 | $579.1 | 6% |
|
| Shares Out (Mil) | 0.7 | 43.0 | 3% |
|
| Institutional Ownership | 96.4% | 84.3% | 70% |
|
| Float (Mil) | 1.5 | 46.8 | 4% |
|
| Beta | 0.54 | 0.62 | 30% |
|
| Avg Daily Volume (000s) | 9 | 285 | 16% |
|
| Price Change (52-week) |
(23.7%) | 63.8% | 28% |
|
| Growth | CNSP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (10.8%) | (1.4%) | 28% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CNSP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($17) | ($11) | 25% |
|
| EPS (TTM) | ($29.673) | ($0.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($6) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $522 | 5% |
|
| Valuation | CNSP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 64.63 | 2.73 | 99% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CNSP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (179.2%) | (24.6%) | 2% |
|
| ROE | (298.6%) | (19.7%) | 3% |
|
| Liabilities to Assets | 98.5% | 35.5% | 94% |
|
| F-Score | 2 | 3 | na |
|
CNS Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
